<?xml version="1.0" encoding="UTF-8"?>
<ReportSnapshot Major="1" Minor="0" Revision="1">
	<CoIDs>
		<CoID Type="RepNo">A48A5</CoID>
		<CoID Type="CompanyName">AstraZeneca plc</CoID>
	</CoIDs>
	<Issues>
		<Issue ID="1" Type="C" Desc="Common Stock" Order="1">
			<IssueID Type="Name">Ordinary Shares</IssueID>
			<IssueID Type="Ticker">AZN</IssueID>
			<IssueID Type="CUSIP">G9885J102</IssueID>
			<IssueID Type="ISIN">GB0009895292</IssueID>
			<IssueID Type="RIC">AZN.L</IssueID>
			<IssueID Type="SEDOL">0989529</IssueID>
			<IssueID Type="DisplayRIC">AZN.L</IssueID>
			<IssueID Type="InstrumentPI">285840</IssueID>
			<IssueID Type="QuotePI">1049533</IssueID>
			<Exchange Code="LON" Country="GBR">London Stock Exchange (LON)</Exchange>
		</Issue>
	</Issues>
	<CoGeneralInfo>
		<CoStatus Code="1">Active</CoStatus>
		<CoType Code="EQU">Equity Issue</CoType>
		<LastModified>2016-02-16</LastModified>
		<LatestAvailableAnnual>2015-12-31</LatestAvailableAnnual>
		<LatestAvailableInterim>2015-12-31</LatestAvailableInterim>
		<Employees LastUpdated="2014-12-31">57500</Employees>
		<SharesOut Date="2016-01-31" TotalFloat="1261280660.0">1264162740.0</SharesOut>
		<ReportingCurrency Code="USD">U.S. Dollars</ReportingCurrency>
		<MostRecentExchange Date="2016-02-22">1.0</MostRecentExchange>
	</CoGeneralInfo>
	<TextInfo>
		<Text Type="Business Summary" lastModified="2015-12-18T05:19:20">AstraZeneca PLC (AstraZeneca) is a global biopharmaceutical company. The Company discovers, develops and commercializes prescription medicines for cardiovascular and metabolic diseases; oncology; respiratory, inflammation and autoimmunity, and infection, neuroscience and gastrointestinal. Its medicines include Crestor for managing cholesterol levels; Seloken/Toprol-XL for hypertension, heart failure and angina; Iressa for lung cancer; Faslodex for breast cancer; Zoladex for prostate and breast cancer; Nexium for acid-related diseases; Seroquel XR for schizophrenia, bipolar disorder and depressive disorder, and Synagis for RSV (respiratory syncytial virus), a respiratory infection in infants. It also offers potassium-binding compound sodium zirconium cyclosilicate (ZS-9), a treatment for hyperkalaemia, a condition associated with increased mortality in patients with chronic kidney disease (CKD), diabetes mellitus (DM) and chronic heart failure (CHF). </Text>
		<Text Type="Financial Summary" lastModified="2016-02-16T00:34:05">BRIEF: For the fiscal year ended 31 December 2015, AstraZeneca plc revenues decreased 7% to $24.71B. Net income increased from $1.23B to $2.83B. Revenues reflect Product sales decrease of 9% to $23.64B. Net income reflects Selling, General decrease of 15% to $10.49B (expense), Other operating income and expense increase from $627M to $1.5B (income), Other operating income exp Restructurin decrease from $292M (expense) to $0K.</Text>
	</TextInfo>
	<contactInfo lastUpdated="2016-02-19T02:16:59">
		<streetAddress line="1">- Legal Department, 2 Kingdom Street</streetAddress>
		<streetAddress line="2"></streetAddress>
		<streetAddress line="3"></streetAddress>
		<city>LONDON</city>
		<state-region></state-region>
		<postalCode>W2 6BD</postalCode>
		<country code="GBR">United Kingdom</country>
		<contactName>Thomas Larsen</contactName>
		<contactTitle>IR Contact Officer</contactTitle>
		<phone>
			<phone type="mainphone">
				<countryPhoneCode>44</countryPhoneCode>
				<city-areacode>20</city-areacode>
				<number>73045000</number>
			</phone>
			<phone type="mainfax">
				<countryPhoneCode>44</countryPhoneCode>
				<city-areacode>20</city-areacode>
				<number>76048151</number>
			</phone>
			<phone type="contactphone">
				<countryPhoneCode>44</countryPhoneCode>
				<city-areacode>20</city-areacode>
				<number>76048127</number>
			</phone>
		</phone>
	</contactInfo>
	<webLinks lastUpdated="2012-08-30T00:22:28"><webSite mainCategory="Home Page">http://www.astrazeneca.com/</webSite><eMail mainCategory="Company Contact/E-mail"></eMail></webLinks>
	<peerInfo lastUpdated="2016-02-19T02:16:59">
		<IndustryInfo>
			<Industry type="TRBC" order="1" reported="0" code="5620104010" mnem="">Pharmaceuticals - NEC</Industry>
			<Industry type="NAICS" order="1" reported="0" code="325412" mnem="">Pharmaceutical Preparation  Manufacturing</Industry>
			<Industry type="NAICS" order="2" reported="0" code="42221" mnem="">Drug, Drug Proprietaries and Druggists' Sundries Wholesalers</Industry>
			<Industry type="NAICS" order="3" reported="0" code="54171" mnem="">Research and Development in the Physical, Engineering, and Life Sciences</Industry>
			<Industry type="NAICS" order="4" reported="0" code="551112" mnem="">Offices of  Other Holding Companies</Industry>
			<Industry type="SIC" order="0" reported="1" code="2834" mnem="">Pharmaceutical Preparations</Industry>
			<Industry type="SIC" order="1" reported="0" code="2834" mnem="">Pharmaceutical Preparations</Industry>
			<Industry type="SIC" order="2" reported="0" code="5122" mnem="">Drugs/proprietaries/sundries</Industry>
			<Industry type="SIC" order="3" reported="0" code="8731" mnem="">Commercial Physical Research</Industry>
			<Industry type="SIC" order="4" reported="0" code="6719" mnem="">Holding Companies, Nec</Industry>
		</IndustryInfo>
	</peerInfo>
	<officers>
		<officer rank="1" since="10/01/2012">
			<firstName>Pascal</firstName>
			<mI></mI>
			<lastName>Soriot</lastName>
			<age>56 </age>
			<title startYear="2012" startMonth="10" startDay="01" iD1="CEO" abbr1="CEO" iD2="EDR" abbr2="Exec. Dir.">Chief Executive Officer, Executive Director</title>
		</officer>
		<officer rank="2" since="2013">
			<firstName>Marc</firstName>
			<mI></mI>
			<lastName>Dunoyer</lastName>
			<age>62 </age>
			<title startYear="2013" startMonth="11" startDay="01" iD1="CFO" abbr1="CFO" iD2="EDR" abbr2="Exec. Dir.">Chief Financial Officer, Executive Director</title>
		</officer>
		<officer rank="3" since="09/2014">
			<firstName>Fiona</firstName>
			<mI></mI>
			<lastName>Cicconi</lastName>
			<age></age>
			<title startYear="2014" startMonth="09" startDay="" iD1="EVP" abbr1="Exec. VP" iD2="DHR" abbr2="Dir.-HR">Executive Vice-President, Human Resources</title>
		</officer>
		<officer rank="4" since="09/15/2015">
			<firstName>Sean</firstName>
			<mI></mI>
			<lastName>Bohen</lastName>
			<age></age>
			<title startYear="2015" startMonth="09" startDay="15" iD1="EVP" abbr1="Exec. VP" iD2="" abbr2="">Chief Medical Officer, Executive Vice President - Global Medicines Development</title>
		</officer>
		<officer rank="5" since="01/2013">
			<firstName>Ruud</firstName>
			<mI></mI>
			<lastName>Dobber</lastName>
			<age></age>
			<title startYear="2013" startMonth="01" startDay="" iD1="EVP" abbr1="Exec. VP" iD2="" abbr2="">Executive Vice President, Europe</title>
		</officer>
		<officer rank="6" since="01/2013">
			<firstName>Paul</firstName>
			<mI></mI>
			<lastName>Hudson</lastName>
			<age></age>
			<title startYear="2013" startMonth="01" startDay="" iD1="EVP" abbr1="Exec. VP" iD2="" abbr2="">President, AstraZeneca, US and Executive Vice-President, North America</title>
		</officer>
		<officer rank="7" since="01/2013">
			<firstName>Bahija</firstName>
			<mI></mI>
			<lastName>Jallal</lastName>
			<age></age>
			<title startYear="2013" startMonth="01" startDay="" iD1="EVP" abbr1="Exec. VP" iD2="" abbr2="">Executive Vice President, MedImmune</title>
		</officer>
		<officer rank="8" since="01/2013">
			<firstName>Mark</firstName>
			<mI></mI>
			<lastName>Mallon</lastName>
			<age></age>
			<title startYear="2013" startMonth="01" startDay="" iD1="EVP" abbr1="Exec. VP" iD2="" abbr2="">Executive Vice President, International</title>
		</officer>
		<officer rank="9" since="05/2014">
			<firstName>Luke</firstName>
			<mI></mI>
			<lastName>Miels</lastName>
			<age></age>
			<title startYear="2014" startMonth="05" startDay="" iD1="EVP" abbr1="Exec. VP" iD2="" abbr2="">Executive Vice-President, GPPS</title>
		</officer>
		<officer rank="10" since="01/2013">
			<firstName>Menelas</firstName>
			<mI></mI>
			<lastName>Pangalos</lastName>
			<age></age>
			<title startYear="2013" startMonth="01" startDay="" iD1="EVP" abbr1="Exec. VP" iD2="" abbr2="">Executive Vice President - Innovative Medicines</title>
		</officer>
	</officers>
	<Ratios PriceCurrency="GBP" ReportingCurrency="USD" ExchangeRate="0.70681" LatestAvailableDate="2015-12-31">
		<Group ID="Price and Volume">
			<Ratio FieldName="NPRICE" Type="N">41.30500</Ratio>
			<Ratio FieldName="NHIG" Type="N">49.31682</Ratio>
			<Ratio FieldName="NLOW" Type="N">37.46000</Ratio>
			<Ratio FieldName="PDATE" Type="D">2016-02-23T00:00:00</Ratio>
			<Ratio FieldName="VOL10DAVG" Type="N">3.26511</Ratio>
			<Ratio FieldName="EV" Type="N">58012.08100</Ratio>
		</Group>
		<Group ID="Income Statement">
			<Ratio FieldName="MKTCAP" Type="N">52216.24000</Ratio>
			<Ratio FieldName="AREV" Type="N">17463.86000</Ratio>
			<Ratio FieldName="AEBITD" Type="N">5654.48000</Ratio>
			<Ratio FieldName="ANIAC" Type="N">1996.73800</Ratio>
		</Group>
		<Group ID="Per share data">
			<Ratio FieldName="AEPSXCLXOR" Type="N">1.57845</Ratio>
			<Ratio FieldName="AREVPS" Type="N">13.80542</Ratio>
			<Ratio FieldName="ABVPS" Type="N">10.34084</Ratio>
			<Ratio FieldName="ACSHPS" Type="N">3.83265</Ratio>
			<Ratio FieldName="ACFSHR" Type="N">3.17254</Ratio>
			<Ratio FieldName="ADIVSHR" Type="N">1.97907</Ratio>
		</Group>
		<Group ID="Other Ratios">
			<Ratio FieldName="AGROSMGN" Type="N">81.83584</Ratio>
			<Ratio FieldName="AROEPCT" Type="N">14.82278</Ratio>
			<Ratio FieldName="APR2REV" Type="N">2.98996</Ratio>
			<Ratio FieldName="APEEXCLXOR" Type="N">26.16811</Ratio>
			<Ratio FieldName="APRICE2BK" Type="N">3.99436</Ratio>
			<Ratio FieldName="Employees" Type="N">57500</Ratio>
		</Group>
	</Ratios>
	<ForecastData ConsensusType="Mean" CurFiscalYear="2016" CurFiscalYearEndMonth="12" CurInterimEndCalYear="2016" CurInterimEndMonth="3" EarningsBasis="PRX">
		<Ratio FieldName="ConsRecom" Type="N">
			<Value PeriodType="CURR">2.4242</Value>
		</Ratio>
		<Ratio FieldName="TargetPrice" Type="N">
			<Value PeriodType="CURR">49.69680</Value>
		</Ratio>
		<Ratio FieldName="ProjLTGrowthRate" Type="N">
			<Value PeriodType="CURR">1.4404</Value>
		</Ratio>
		<Ratio FieldName="ProjPE" Type="N">
			<Value PeriodType="CURR">14.48114</Value>
		</Ratio>
		<Ratio FieldName="ProjSales" Type="N">
			<Value PeriodType="CURR">16376.44009</Value>
		</Ratio>
		<Ratio FieldName="ProjSalesQ" Type="N">
			<Value PeriodType="CURR">4095.25424</Value>
		</Ratio>
		<Ratio FieldName="ProjEPS" Type="N">
			<Value PeriodType="CURR">2.85233</Value>
		</Ratio>
		<Ratio FieldName="ProjEPSQ" Type="N">
			<Value PeriodType="CURR">0.70186</Value>
		</Ratio>
		<Ratio FieldName="ProjProfit" Type="N">
			<Value PeriodType="CURR">3912.46978</Value>
		</Ratio>
		<Ratio FieldName="ProjDPS" Type="N">
			<Value PeriodType="CURR">1.94670</Value>
		</Ratio>
	</ForecastData>
</ReportSnapshot>
